An Unparalleled Solution
to the Cell and Gene Therapy Manufacturing Dilemma

OrganaBio’s Vision

To transform a world of cell and gene research into one of cell and gene therapies.

Cell-and gene-therapies have advanced considerably in recent years, exciting the scientific and medical communities with their promise as a new treatment paradigm for various intractable diseases. While great strides have been made in the development of such therapies, infrastructure constraints prevent this high-value industry from realizing its full potential and from making new therapies available.

Significant Supply Limitations

Cell and gene therapy is transforming the face of medicine at a rapid rate. With over 1,000 global Regenerative Medicine companies, the industry stands at the precipice of delivering life-saving and life-altering therapies. However, A lack of access to readily-available and rentable cGMP manufacturing space is stifling the industry’s potential. All product developers need access to cleanrooms to deliver therapies to patients, but the industry has forced them to choose between two equally unattractive options:

Option A:

Build A Custom Facility

  • Incur large capital expense in brick and mortar
  • Must assemble team of experts (architects, engineers, developers, etc)
  • 2+ years to move-in; Must be able to predict future capacity needs
  • Diverts critical resources from advancement of your technology platform

Option B:

Outsource Manufacturing

  • Necessitates costly and time-intensive technology transfer of proprietary information
  • Fraught with scheduling constraints & time delays based on availability
  • Incur large expenses in clean room reservation fees
  • Cede control over your process; Must accept limited transparency

We can do better.
Enter Option C

The Obvious Choice

Catalyzing the clinical translation of cell and gene therapies by democratizing access to cGMP manufacturing space and expertise.

Tell Me More

Let’s discuss your research and manufacturing needs. Contact Us today.